Coya Therapeutics, Inc. (COYA) stock
Close on Nov 12, 2026Market cap $76.71MP/E –Yield –
Coya Therapeutics, Inc. grew revenue 17.6% to $4.69M over the twelve months to Sep 30, 2026. At the latest close the market valued the company at $76.71M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $76.71M
- P/E ratio
- –
- Price to sales
- 16.36
- Price to book
- 2.29
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $4.69M
- Net income
- -$30.17M
- EPS, diluted
- -$1.39
- Book value per share
- $1.43
- Diluted shares
- 23M
Trading
- Next earnings
- Mar 15, 2027 (estimated, before the open)
- Previous close
- $3.21
- Open
- $3.19
- Day's range
- $3.05 – $3.41
- Volume
- 141,124
- Average volume (20 days)
- 174,773
- Beta (5 years)
- 1.20
- 52-week range
- $2.72 – $6.62
- RSI (14 days)
- 37.1
- Volatility (1 year)
- 62.4%
- Relative volume
- 0.83×
- WACC
- 10.9%
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | COYA | S&P 500 | Difference | COYA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -32.0% | -2.7% | −29.3 pts | ||
| 3 months | -30.3% | -1.7% | −28.5 pts | ||
| Year to date | -43.6% | +11.9% | −55.5 pts | ||
| 1 year | -46.3% | +12.0% | −58.3 pts | ||
| 3 years | -35.2% | +78.2% | −113.4 pts | -13.5% | +21.2% |
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Press releases
Releases Coya Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Update
- Results
About Coya Therapeutics
Pharmaceutical Preparations
Coya Therapeutics, Inc. is a clinical-stage biotechnology company that develops therapies designed to enhance the function of regulatory T cells, or Tregs. The company explores three therapeutic modalities: Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Its pipeline addresses neurodegenerative, autoimmune, and metabolic diseases, with primary focus on conditions such as amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's disease, and Parkinson's disease. Its lead candidate, COYA 302, is a combination biologic utilizing low-dose interleukin-2 alongside a fusion protein. Another candidate, COYA 303, combines low-dose interleukin-2 with a GLP-1 receptor agonist for inflammatory conditions. Because its product candidates remain in clinical and preclinical development, the company does not have commercial customers.
Company profile, executives and historyCoya Therapeutics stock: common questions
What is Coya Therapeutics's stock price?
COYA closed at $3.27 on Nov 12, 2026, up 1.87% on the day. Over the past 52 weeks it traded between $2.72 and $6.62.
What is Coya Therapeutics's market cap?
Coya Therapeutics was worth $76.71M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is COYA's P/E ratio?
Coya Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.39), so it has no meaningful P/E ratio.
How much revenue does Coya Therapeutics make?
Coya Therapeutics reported revenue of $4.69M for the twelve months to Sep 30, 2026, up 17.6% from a year earlier.
Does Coya Therapeutics pay a dividend?
No. Coya Therapeutics has not paid a cash dividend over the last twelve months.
When does Coya Therapeutics report earnings next?
Coya Therapeutics is expected to report Q4 FY2026 results on Mar 15, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has COYA stock performed over the past year?
Including dividends, COYA returned -46.3% over the past year, against +12.0% for the S&P 500.
How many COYA shares are sold short?
1M shares were sold short at the latest FINRA report, 6.34% of the float, or 11.9 days of average trading volume.
Who are Coya Therapeutics's competitors?
Companies most similar to Coya Therapeutics by business, industry and size include ACIU, CAMP, HCWB, TRDA, ALMS.
See a number that looks wrong?